T umor-induced osteomalacia (TIO) is a paraneoplastic disorder caused by small mesenchymal tumors that produce high levels of the hormone fibroblast-growth-factor 23 (FGF23). Complete surgical resection leads to cure; however, these tumors are notoriously difficult to locate due to their small size.
In our recent series of subjects with TIO, we found that successful localization was achieved in only 61% of subjects, even with a combination of localization studies that included two functional imaging modalities, 111 In-pentetreotide single-photon emission computed tomography (SPECT) (Octreoscan-SPECT/CT) and fluorodeoxyglucose-positron emission tomography ( 18 F FDG-PET/CT), anatomical localization studies (magnetic tomography imaging [MRI] and CT), and as needed, selective venous sampling (1) . Recent reports suggest 68 Gallium ( 68 Ga)-conjugated somatostatin peptide analogues, such as DOTATATE PET/CT may be useful at identifying phosphaturic mesenchymal tumors (PMTs), but in none of these reports was there a direct comparison to conventional studies, including both Octreoscan-SPECT/CT and 18 F FDG-PET together (2) (3) (4) . The possible superiority of 68 Ga-DOTATATE lies in its higher affinity than Octreoscan for somatostatin receptors 2 and 5, which PMTs express (3, 5) . Furthermore, the optimal physical characteristics of 68 Ga (PET emitter) enables faster acquisition of images and lower radiation dose, in addition to the vastly superior performance of PET imaging over scintigraphy in the case of Octreoscan-SPECT/CT. In this prospective study, we compared 68 Ga-DOTATATE PET/CT vs Octreoscan SPECT/CT and 18 F FDG-PET/CT scan in subjects with TIO referred to a tertiary referral center for tumor localization over a 12-month period.
Subjects and Methods
The diagnosis of TIO was based upon an acquired condition of hypophosphatemia from renal phosphate wasting and an elevated blood FGF23. The onset of symptoms (weakness, multiple fractures) occurred within 2-24 years of presentation, with a median of 7 years (Table 1) . All patients had a biochemical profile consistent with TIO, including low serum phosphorus and 1,25-dihdroxyvitamin D, low tubular reabsorption of phosphorus, and an elevated blood FGF23, as measured by an intact FGF23 ELISA assay (Kainos or Immutopics) or C-terminus ELISA assay (Immutopics) for patient 1. All subjects had failed tumor localization at least once before referral. Four subjects had had prior surgical attempts. Subject 4, who was ultimately shown to have metastatic disease, had undergone four failed surgical attempts previously (all in the right mandible, where the primary tumor originated). Subject 5 had had an unsuccessful attempt at tumor resection in the right foot based on false-positive 18 F FDG-PET/CT imaging. Subject 6 had had a PMT resected from the left femur that resulted in normalization of blood phosphate and FGF23. However, tumor margins were not identified and there was local recurrence, which resulted in the need for reoperation. Subject 9 had had a PMT resected from the maxilla, and although tumor margins showed PMT, blood phosphate and FGF23 initially normalized and she was deemed cured. Disease recurred several years later at the same location.
Subjects were admitted to the National Institutes of Health (NIH) Clinical Center between February 2014 and February 2015 and gave informed consent to be enrolled in studies that were approved by the National Institute of Dental and Craniofacial Research and the National Cancer Institute Institutional review boards. Biochemical evaluation to confirm TIO included blood phosphate, FGF23, 25-hydroxy-and 1,25-dihydroxyvitamin D, PTH, and calculation of tubular reabsorption of phosphate, as previously described (1) . Imaging studies included 68 Ga-DOTATATE PET/CT (as described later), Octreoscan-SPECT/CT scan, and 18 F FDG-PET/CT (in two cases, subjects 9 and 10, the 18 F FDG-PET/CT study had been previously performed recently and was not repeated). Anatomical imaging with MRI and CT, and selective venous sampling were performed to confirm tumor localization before resection, as needed. Surgical resection was performed if the tumor was localized, with normalization of blood phosphate off of supplementation following tumor resection to prove cure (Table 1) .
Imaging
DOTATATE is an amide of the acid DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), which acts as a chelator for the radionuclide to (Tyr Ga-DOTATATE PET/CT was recently approved by the US Food and Drug Administration for clinical use (6) ; however, at the time of the study, it was classified as an investigational agent in the United States, therefore the study was performed under a research protocol approved by the National Cancer Institute Institutional Review Board and the NIH Radiation Safety Committee (NCT01967537) under an Investigational New Drug application from the US Food and Drug Administration. Through a peripheral vein, approximately 5 mCi of 68 Ga-DOTATATE was administered. After approximately 60 minutes, the patient was positioned in the supine position in a PET/CT scanner (Siemens mCT), and images from the toes to top of the skull, including extremities, were obtained. A low-dose, noncontrast CT was used for attenuation correction and anatomic localization. Maximum standardized uptake values (SUVmax) were normalized by body weight. An Octreoscan-SPECT/CT with imaging at 4 and 24 hours after IV administration of approximately 6 mCi (222 MBq) of 111In-pentetreotide was performed within 6 weeks of 68 Ga-DOTATATE PET/CT to allow for direct comparison. All subjects underwent whole-body 18 F FDG-PET/CT either during the same admission (nine of 11) or during a previous evaluation at the NIH (two of 11). For anatomical confirmation additional imaging studies, included CT and MRI of suspicious areas were performed.
Images were reviewed by independent radiologists and nuclear medicine physicians in a blinded fashion. All imaging studies were analyzed and correlated with clinical information by a multidisciplinary team to determine the optimal treatment options based on the functional status of the tumors and/or the presence of metastatic disease.
Results
The cohort consisted of 11 subjects (six females, five males), with mean age of age of 38 (range, 19 -60) ( Table 1) . Seven of 11 subjects had findings on (patients 3, 6, 8, 9) . After confirmation by anatomical imaging and selective venous sampling, the location of the tumor in subject 2 was judged to be such that that surgery would have been highly morbid. Therefore, he underwent catheter-guided embolization and cryoablation and was cured. Subject 4 had unresectable, widely metastatic disease and was enrolled in clinical trial with the fibroblast growth receptor-inhibitor NVP-BGJ398 (NCT02160041) with a promising response (7). Subject 11 had findings that were ultimately considered to be false positive after anatomical imaging and venous sampling failed to support the 68 Ga-DOTATATE finding as that of a PMT.
Five of the 11 subjects had suggestive findings on Octreoscan-SPECT/CT. In all five cases, the lesion was also seen on 68 Ga-DOTATATE imaging. One was subject 11, mentioned previously, in whom all three imaging modalities gave a false-positive reading. Six of 11 subjects had positive 18 F FDG-PET/CT scans; five were also positive on 68 Ga-DOTATATE. In total, two 18 F FDG-PET/CT scans were considered to be false positive.
68 Ga-DOTATATE showed suspicious lesions that were not seen with Octreoscan-SPECT/CT in two cases, both of which eventually proved to be the culprit tumor, and both of which were also seen on 18 F FDG-PET/CT scan. Comparison of images of all three modalities in subjects 2, 3, and 9 are shown in Figures 1, 2 , and 3 respectively.
Discussion
The culprit tumor was successfully localized and treated in 54.5% (6/11) of subjects, including one patient with metastatic disease; and not localized in 45.5% (5/11). Ga-DOTATATE imaging correlated with Octreoscan-SPECT/CT in 9/11 cases, and detected lesions in 2/11 cases not seen on Octreoscan-SPECT/CT but seen on 18 F FDG-PET/CT, both of which were confirmed to represent the culprit tumor (Table 1) . Interestingly, four of five subjects with localized tumors had intact FGF23 levels higher than 1000 pg/ml (subjects 2, 3, 6, 8), suggesting that markedly elevated levels of FGF23 may be associated with larger and/or tumors that have stronger somatostatin receptor (SSTR) uptake on imaging. Findings on 68
Ga-DOTATATE imaging were accurate in localizing tumor in six of seven cases, and proved to be false positive in one; Octreoscan-SPECT/CT was accurate in four of the five positive imaging studies and false positive in one of five; 18 F FDG-PET/CT was accurate in four of six positive studies and false negative in two of six. Based on these findings, the sensitivity and specificity of a With the exception of subject 1 who underwent measurement of C-terminus FGF23 (normal range Ͻ180 RU/ml), all patients underwent measurement of intact FGF23 (normal range 8 -78 pg/ml). b Subject had one or more surgical procedures to resect tumor before the study.
c Ultimately considered to be false positive as determined by biopsy and/or venous sampling, and/or surgical resection.
doi: 10.1210/jc.2016-2052 press.endocrine.org/journal/jcem 3577 from 14 patients with TIO, and found diffuse and strongly positive SSTR2A staining in all tumors (3). Thus, the proposed superiority of 68 Ga-DOTATATE imaging over Octreoscan-SPECT/CT imaging may be based on the higher affinity of 68 Ga-DOTA-conjugated peptides for SSTR2 receptors as compared to Octreoscan-SPECT/CT (5). In addition to the higher affinity of 68 Ga-DOTATATE for SSTR2, Octreoscan-SPECT/CT is limited by relatively poor spatial resolution compared to PET, thus accounting for why SSTR-imaging using 68 Ga-DOTATATE enables better visualization of organs with higher octreotide-physiologic uptake (eg, liver). Additionally, 68 Ga-DOTATATE imaging provides advantages in shorter acquisition time and lower radiation exposure because of its short half-life of 68 minutes, compared with 2.8 days for 111 In, the isotope used in Octreoscan-SPECT/CT imaging (5). The presumed greater sensitivity of 68 Ga-DOTATATE as compared to Octreoscan is accounted for both the radiotracer ( 68 Ga), which is a positron emitter that enables STTR imaging with PET and the use of higher affinity to somatostatin receptors compounds like DOTATATE.
In the largest retrospective study published to date evaluating 68 Ga-DOTATATE imaging in TIO, Zhang and colleagues found that 68 Ga-DOTATATE imaging was positive in 32 of 32 subjects who had TIO confirmed pathologically; however, patients with negative 68 Ga-DOTATATE imaging were excluded from the analysis as not having TIO, whereas the cause of the hypophosphatemia in at least half of the patients was unclear (12) . No comparison to other imaging modalities was performed.
Clifton-Bligh et al were the first to study the localization of TIO tumors using 68 Ga-DOTATATE imaging and successfully localized TIO tumors in six of six cases (10).
However, Octreoscan-SPECT/CT was performed in only one case, along with other imaging modalities such as 18 F FDG-PET (performed in two of six patients) or TcSestamibi scan (performed in one of six) (only 68 Ga-DOTATATE imaging localized the tumors) (10) . Although the study found 100% sensitivity and specificity for 68 Ga-DOTATATE, the study was retrospective and included only a subset of patients with presumed TIO. It is unclear if the other subjects with suspected TIO and in whom the tumor was not localized had 68 Ga-DOTATATE imaging. In a study similar to ours, Breer et al compared the efficacy of 68 Ga-DOTATATE to Octreoscan-SPECT/CT for tumor localization in five patients with TIO (three females, two males) (3). Whereas only one of five cases showed focal uptake by Octreoscan-SPECT/CT, all five cases showed focal activity on 68 Ga-DOTATATE imaging. All subjects were cured after surgical resection. However, the low sensitivity of Octreoscan-SPECT/CT in this study is likely due to the fact that SPECT was not performed from head to feet as in our study, but confined to suspicious regions identified on planar images. Two Tc-HYNIC-Octreoscan, which had 100% sensitivity and specificity in all six patients undergoing this imaging (4) . A recent case series also described the successful use of 68 Ga-DOTA peptide PET/CT imaging in localizing PMT tumors in all three of three patients presenting with TIO (13) . 68 Ga-DOTANOC has been evaluated in one study of 10 TIO patients showing a sensitivity and specificity of 90% (9) . Several case reports also report successful localization using this radiopharmaceutical (14 -16) . 68 Ga-DOTATOC has also been described in the successful localization of PMT in an adolescent boy (17) .
Other imaging modalities studied include 99 Tc-HYNICOctreoscan, with a sensitivity and specificity of 86.3% and 99.1%, respectively (18) , and 99 Tc-octretide in which 49% had positive imaging and 41% were found to have TIO (19) . In this cohort, we found that 68 Ga-DOTATATE as a single study provided the highest sensitivity/specificity. However it was not superior to our previously reported sensitivity and specificity of combined Octreoscan-SPECT/CT and 18 F FDG-PET in localization of PMTs (1).
Although our study showed high specificity for all three imaging modalities used, it showed low sensitivity for all three. In the case of 68 Ga-DOTATATE, the sensitivity of 54.5% for 68 Ga-DOTATATE is the lowest reported among other published studies, which have reported sensitivities of 83-100% (2-4, 10, 12) . This difference is probably best explained by the fact this cohort consisted of subjects who had previously failed extensive, sometimes multiple, localization attempts before being seen at our center, and in some cases had failed localization at our center before the availability of 68 Ga-DOTATATE imaging. Therefore, this likely represents a group of tumors that are extremely small and difficult to localize. Although comprehensive testing was performed to rule out other acquired forms of hypophosphatemia, such as Fanconi syndrome, heavy metal exposure, etc., other as-yet unknown causes of this disorder may exist. An important feature of this study is the fact that it was prospective. Previously published studies were retrospective and, as such, may have excluded subjects with negative imaging and/or reclassified them as having alternative causes of hypophosphatemia. This would significantly raise the sensitivity found in such studies. In this prospective study, we consider negative images as failed localization attempts, thus significantly reducing the sensitivities of the reported imaging modalities. An important feature of this study and previous work in this area from our institution is the manner in which the Octreoscan-SPECT/CT is performed. SPECT imaging is typically performed from head to toe, an approach that can require 5-6 hours of scanning time over 2 days; an approach that is undertaken at few other centers, but necessary to maximize the sensitivity of Octreoscan-SPECT/CT in localizing PMTs. Because 68 Ga-DOTATATE was only recently approved by the US Food and Drug Administration for clinical use in the detection of rare neuroendocrine tumors (6) , and a cost structure has not been established; therefore, a cost-benefit analysis at this time is not possible. Finally, an important limitation in this study is the small number of subjects. Potential studies characterizing SSTR pattern and its correlation to imaging response may prove useful. Future studies with similar comparison imaging modalities will be needed to definitively define the ideal single imaging study for identifying PMTs.
Conclusion
In this first prospective study of SSTR imaging using 68 Ga-DOTATATE in TIO, 68 Ga-DOTATATE PET/CT had greater sensitivity and specificity than either Octreoscan-SPECT/CT or 18 F FDG-PET/CT but was not more sensitive than Octreoscan-SPECT/CT and 
